{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:31:38Z","timestamp":1782876698401,"version":"3.54.5"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin City","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Progressive retinal neuroaxonal damage after acute optic neuritis may occur in neuromyelitis optica spectrum disorder (NMOSD). However, it is unclear if treatments used to prevent attacks influence neurodegeneration.<\/jats:p><jats:p><jats:bold>Objectives:<\/jats:bold> We aimed to investigate retinal damage in patients treated with disease-modifying drugs in a longitudinal study.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We retrospectively included 50 patients with aquaporin 4-antibody-seropositive NMOSD. Peripapillary retinal nerve fiber layer (pRNFL) thickness, macular ganglion cell complex (mGCC) thickness, total macular volume (TMV), and optic disc measures were acquired by spectral domain optical coherence tomography in patients treated with tocilizumab, rituximab, and azathioprine.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Longitudinally, in eyes with a history of ON (NMOSD<jats:sup>ON+<\/jats:sup>), we observed annual thinning of mGCC [tocilizumab: \u22121.77 (\u22123.44, \u22120.09) \u03bcm, <jats:italic>p<\/jats:italic> = 0.041; rituximab: \u22122.03 (\u22123.58, \u22120.48) \u03bcm, <jats:italic>p<\/jats:italic> = 0.017; azathioprine: \u22121.79 (\u22122.22, \u22121.37) \u03bcm, <jats:italic>p<\/jats:italic> &amp;lt; 0.001], and pRNFL [tocilizumab: \u22122.07 (\u22120.75, \u22123.39) \u03bcm, <jats:italic>p<\/jats:italic> = 0.005; rituximab: \u22122.18 (\u22120.36, \u22124.00) \u03bcm, <jats:italic>p<\/jats:italic> = 0.023; azathioprine: \u22122.37 (\u22120.98, \u22123.75) \u03bcm, <jats:italic>p<\/jats:italic> = 0.003], reduced TMV [tocilizumab: \u22120.12 (\u22120.22, \u22120.01) mm<jats:sup>3<\/jats:sup>, <jats:italic>p<\/jats:italic> = 0.028; rituximab: \u22120.15 (\u22120.21, \u22120.08) mm<jats:sup>3<\/jats:sup>, <jats:italic>p<\/jats:italic> = 0.001; azathioprine: \u22120.12 (\u22120.20, \u22120.04) mm<jats:sup>3<\/jats:sup>, <jats:italic>p<\/jats:italic> = 0.006], and increased cup area [tocilizumab: 0.08 (\u22120.01, 0.16) mm<jats:sup>2<\/jats:sup>, <jats:italic>p<\/jats:italic> = 0.010; rituximab: 0.07 (0.01, 0.12) mm<jats:sup>2<\/jats:sup>, <jats:italic>p<\/jats:italic> = 0.019; azathioprine: 0.14 (0.02, 0.26) mm<jats:sup>2<\/jats:sup>, <jats:italic>p<\/jats:italic> = 0.023]. However, we detected no significant differences in annual changes in mGCC, pRNFL, TMV, and cup area between patients with tocilizumab, rituximab, and azathioprine in NMOSD<jats:sup>ON+<\/jats:sup> eyes. NMOSD<jats:sup>ON\u2212<\/jats:sup> eyes did not display mGCC or pRNFL thinning in patients treated with tocilizumab and rituximab. Intriguingly, we observed significant thinning of mGCC in patients treated with azathioprine compared with tocilizumab [\u22120.84 (\u22121.50, \u22120.18) \u03bcm vs. \u22120.19 (\u22120.87, 0.48) \u03bcm, <jats:italic>p<\/jats:italic> = 0.012] and rituximab [\u22120.84 (\u22121.50, \u22120.18) \u03bcm vs. \u22120.07 (\u22121.25, \u22122.51) \u03bcm, <jats:italic>p<\/jats:italic> = 0.015] in NMOSD<jats:sup>ON\u2212<\/jats:sup> eyes.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> This study demonstrated that retinal ganglion cell loss is independent of ON attacks in NMOSD. Tocilizumab and rituximab may delay mGCC thinning in NMOSD<jats:sup>ON\u2212<\/jats:sup> eyes compared with azathioprine.<\/jats:p>","DOI":"10.3389\/fneur.2021.669567","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T05:43:47Z","timestamp":1626673427000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Optical Coherence Tomography Reveals Longitudinal Changes in Retinal Damage Under Different Treatments for Neuromyelitis Optica Spectrum Disorder"],"prefix":"10.3389","volume":"12","author":[{"given":"Pei","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moli","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda","year":"2019","journal-title":"Clin Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1093\/brain\/awq146","article-title":"A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials","volume":"133","author":"Henderson","year":"2010","journal-title":"Brain."},{"key":"B3","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1093\/brain\/awr264","article-title":"Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis","volume":"135","author":"Syc","year":"2012","journal-title":"Brain."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1136\/jnnp-2018-318382","article-title":"Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study","volume":"89","author":"Oertel","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1177\/1352458519861603","article-title":"Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography","volume":"26","author":"Pisa","year":"2020","journal-title":"Mult Scler."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s00415-016-8138-8","article-title":"Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder","volume":"263","author":"Jeong","year":"2016","journal-title":"J Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1212\/NXI.0000000000000334","article-title":"Microstructural visual system changes in AQP4-antibody-seropositive NMOSD","volume":"4","author":"Oertel","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ana.24030","article-title":"Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis","volume":"75","author":"Gabilondo","year":"2014","journal-title":"Ann Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1177\/1352458517727604","article-title":"Bidirectional degeneration in the visual pathway in neuromyelitis optica spectrum disorder (NMOSD)","volume":"24","author":"Tian","year":"2018","journal-title":"Mult Scler."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1212\/01.wnl.0000345042.53843.d5","article-title":"Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis","volume":"72","author":"Naismith","year":"2009","journal-title":"Neurology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1212\/WNL.0b013e3181af78b8","article-title":"Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies","volume":"73","author":"Ratchford","year":"2009","journal-title":"Neurology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3389\/fneur.2019.01076","article-title":"Retinal degeneration after first-ever optic neuritis helps differentiate multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"10","author":"Kim","year":"2019","journal-title":"Front Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/nrneurol.2017.139","article-title":"Achievements and obstacles of remyelinating therapies in multiple sclerosis","volume":"13","author":"Stangel","year":"2017","journal-title":"Nat Rev Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J Neurol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(16)00004-1","article-title":"Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Raftopoulos","year":"2016","journal-title":"Lancet Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1212\/WNL.0000000000002774","article-title":"The APOSTEL recommendations for reporting quantitative optical coherence tomography studies","volume":"86","author":"Cruz-Herranz","year":"2016","journal-title":"Neurology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e34823","DOI":"10.1371\/journal.pone.0034823","article-title":"The OSCAR-IB consensus criteria for retinal OCT quality assessment","volume":"7","author":"Tewarie","year":"2012","journal-title":"PLoS ONE."},{"key":"B22","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"81","author":"Yang","year":"2013","journal-title":"Neurology."},{"key":"B23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jneuroim.2017.10.001","article-title":"Subclinical retinal atrophy in the unaffected fellow eyes of multiple sclerosis and neuromyelitis optica","volume":"313","author":"Akaishi","year":"2017","journal-title":"J Neuroimmunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/ana.24608","article-title":"Clinicopathological features in anterior visual pathway in neuromyelitis optica","volume":"79","author":"Hokari","year":"2016","journal-title":"Ann Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12974-016-0746-9","article-title":"Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G","volume":"13","author":"Felix","year":"2016","journal-title":"J Neuroinflammation."},{"key":"B26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40478-015-0259-2","article-title":"Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody","volume":"3","author":"Kurosawa","year":"2015","journal-title":"Acta Neuropathol Commun."},{"key":"B27","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1001\/archneur.65.7.920","article-title":"Optical coherence tomography in neuromyelitis optica","volume":"65","author":"de Seze","year":"2008","journal-title":"Arch Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e66151","DOI":"10.1371\/journal.pone.0066151","article-title":"Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis","volume":"8","author":"Schneider","year":"2013","journal-title":"PLoS ONE."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520977771","article-title":"Evidence of subclinical quantitative retinal layer abnormalities in AQP4-IgG seropositive NMOSD","author":"Filippatou","year":"2020","journal-title":"Mult Scler"},{"key":"B30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/WNO.0000000000000404","article-title":"Longitudinal study of retinal nerve fiber layer thickness and macular volume in patients with neuromyelitis optica spectrum disorder","volume":"36","author":"Manogaran","year":"2016","journal-title":"J Neuroophthalmol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/ana.22005","article-title":"Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis","volume":"67","author":"Talman","year":"2010","journal-title":"Ann Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.msard.2019.06.033","article-title":"Intractable axonal neuropathy with multifocal peripheral nerve swelling in neuromyelitis optica spectrum disorders: a case report","volume":"35","author":"Mizuno","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.pain.2013.03.026","article-title":"Inhibition of IL-6 signaling: a novel therapeutic approach to treating spinal cord injury pain","volume":"154","author":"Guptarak","year":"2013","journal-title":"Pain."},{"key":"B34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/ana.23721","article-title":"Cognitive impairment and cortical degeneration in neuromyelitis optica","volume":"73","author":"Saji","year":"2013","journal-title":"Ann Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"6993","DOI":"10.1523\/JNEUROSCI.23-18-06993.2003","article-title":"Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway","volume":"23","author":"Diem","year":"2003","journal-title":"J Neurosci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s13760-017-0795-6","article-title":"Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study","volume":"117","author":"Zhang","year":"2017","journal-title":"Acta Neurol Belg."},{"key":"B38","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder","volume":"385","author":"Yang","year":"2018","journal-title":"J Neurol Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"102166","DOI":"10.1016\/j.msard.2020.102166","article-title":"Efficacy and safety of monoclonal antibody therapy in neuromyelitis optica spectrum disorders: evidence from randomized controlled trials","volume":"43","author":"Xue","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1136\/bjo.2006.092031","article-title":"Quantification of optic nerve head topography in optic neuritis: a pilot study","volume":"90","author":"Trip","year":"2006","journal-title":"Br J Ophthalmol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.669567\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T05:43:51Z","timestamp":1626673431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.669567\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":41,"alternative-id":["10.3389\/fneur.2021.669567"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.669567","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,19]]},"article-number":"669567"}}